New appointment at TopoTarget
This article was originally published in Scrip
Dr François Martelet has joined TopoTarget (Denmark) as CEO with immediate effect, as the company prepares for the commercialisation of its late-stage lead anticancer drug, belinostat, which is partnered with Spectrum Pharmaceuticals. He will replace founder and CEO Professor Peter Buhl Jensen. Dr Martelet was formerly president and CEO of AVAX Technologies, a US cancer vaccines firm, and was previously vice-president and worldwide franchise head of oncology at Merck & Co, where he helped launch Zolinza (vorinostat).